Adverse Events Associated with Melatonin for the Treatment of Primary or Secondary Sleep Disorders: A Systematic Review
| Autor: | Besag Fmc, Vasey Mj, Wong Ick, Lao Ksj |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Sleep Wake Disorders
Pediatrics medicine.medical_specialty Mood swing MEDLINE Melatonin 03 medical and health sciences 0302 clinical medicine Palpitations Humans Medicine Pharmacology (medical) Clinical significance Adverse effect Randomized Controlled Trials as Topic business.industry Consolidated Standards of Reporting Trials Checklist 030227 psychiatry Psychiatry and Mental health Neurology (clinical) medicine.symptom Sleep business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | CNS Drugs. 33:1167-1186 |
| ISSN: | 1179-1934 1172-7047 |
| DOI: | 10.1007/s40263-019-00680-w |
| Popis: | Melatonin is widely available either on prescription for the treatment of sleep disorders or as an over-the-counter dietary supplement. Melatonin has also recently been licensed in the UK for the short-term treatment of jetlag. Little is known about the potential for adverse events (AEs), in particular AEs resulting from long-term use. Concern has been raised over the possible risks of exposure in certain populations including pre-adolescent children and patients with epilepsy or asthma. The aim of this systematic review was to assess the evidence for AEs associated with short-term and longer-term melatonin treatment for sleep disorders. A literature search of the PubMed/Medline database and Google Scholar was conducted to identify randomised, placebo-controlled trials (RCTs) of exogenous melatonin administered for primary or secondary sleep disorders. Studies were included if they reported on both the types and frequencies of AEs. Studies of pre-term infants, studies of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink